Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Immuneering (IMRX) EBITDA (2020 - 2026)

Immuneering's EBITDA history spans 7 years, with the latest figure at -$13.8 million for Q1 2026.

  • On a quarterly basis, EBITDA rose 8.39% to -$13.8 million in Q1 2026 year-over-year; TTM through Mar 2026 was -$54.7 million, a 11.48% increase, with the full-year FY2025 number at -$55.9 million, up 8.34% from a year prior.
  • EBITDA came in at -$13.8 million for Q1 2026, down from -$11.5 million in the prior quarter.
  • The five-year high for EBITDA was -$11.5 million in Q4 2025, with the low at -$18.1 million in Q4 2024.
  • Historically, EBITDA has averaged -$13.8 million across 5 years, with a median of -$13.8 million in 2026.
  • Biggest five-year swings in EBITDA: plummeted 108.92% in 2022 and later soared 36.33% in 2025.
  • Year by year, EBITDA stood at -$13.1 million in 2022, then fell by 14.9% to -$15.1 million in 2023, then fell by 19.68% to -$18.1 million in 2024, then surged by 36.33% to -$11.5 million in 2025, then decreased by 19.87% to -$13.8 million in 2026.
  • Business Quant data shows EBITDA for IMRX at -$13.8 million in Q1 2026, -$11.5 million in Q4 2025, and -$15.0 million in Q3 2025.